Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

June 24, 2026 Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Ninerafaxstat is a first-in-class therapy targeting cardiac energetics and is currently being evaluated in the Phase 2b FORTITUDE-HCM trial in patients with symptomatic nHCM Orphan Drug Designation provides regulatory and development incentives, including enhanced FDA interaction, potential […] The post Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy appea